Boehringer again rises up rare disease reputation rankingsFiercepharma·2 days ago, 01:52 AMBMRN-1.45%AZN+0.91%
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatmentMSN·Aug 19 at 10:32 AMBMRN-1.45%
BioMarin spends up to $490m for Alesta’s bone disease candidatePharmaceutical Technology·Aug 19 at 08:55 AMBMRN-1.45%
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga_article·Aug 19 at 06:55 AMALNY+3.02%BMRN-1.45%
Barclays Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) StockMarket Beat·Aug 17 at 08:42 AMBMRN-1.45%
Persistent Asset Partners Ltd Makes New $4.57 Million Investment in BioMarin Pharmaceutical Inc. $BMRNMarket Beat·Aug 17 at 05:40 AMBMRN-1.45%
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease GrowthMarket Beat·Aug 12 at 09:05 AMBMRN-1.45%FOLD0.00%
BMRN: Amicus integration, VOXZOGO growth, and pipeline expansion fuel rare disease leadershipQuartr·Aug 12 at 08:33 AMBMRN-1.45%FOLD0.00%
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week High on Analyst UpgradeMarket Beat·Aug 10 at 11:40 AMBMRN-1.45%
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston | BMRN Stock NewsStockTitan·Aug 10 at 12:05 AMBMRN-1.45%
HC Wainwright Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock PriceMarket Beat·Aug 7 at 07:12 AMBMRN-1.45%
BioMarin Q2 GAAP net income drops 81% to $45 million; revenue rises 20% to $990 millionPUBT·Aug 6 at 03:13 PMBMRN-1.45%
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To ExpectStock Story·Aug 4 at 10:23 PMBMRN-1.45%AMGN+1.88%
